Source: BUSINESS WIRE
Tuesday, February 09, 2010
HOUSTON--(BUSINESS WIRE)--Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ has
opened up the path to femtomedicine, an entirely new cancer
diagnostics, it was reported today at First Global Congress on
NanoEngineering for Medicine and Biology in Houston, TX.
advertisement
You do not have JavaScript enabled or are using an older version of
Adobe Flash. You can update your version of Adobe Flash here.
Femto-neutrons or ‘femtons’ are fast neutrons of femtometer wavelength,
a million times shorter than the current nanotechnology diagnostic
probes which operate on nanometer scale. In the first experiment of the
kind, a collaboration of California Science & Engineering Corp. (CALSEC)
and College of Medicine, University of California, Irvine (UCI), claimed
that is was able to detect oxygen differences as tiny as 1 atom of
oxygen per molecule. Since ‘hypoxic’ cancerous tumors contain 50% to 90%
less oxygen than healthy tissue, if you find an oxygen difference
between a tumor and the adjacent normal tissue – you have diagnosed
cancer! The principle is named ‘Differential Femto Oximetry’ and the
patented diagnostic probe ‘Oncosensor’.
“We are ready and eager to test this interesting approach in vivo
by making animals inhale carbogen, an oxygen-enriched harmless gas,”
said co-author Orhan Nalcioglu, Professor and Director of the Center for
Functional Onco Imaging of the UCI College of Medicine.
“Our mission is to provide needleless
biopsy with negligible ‘false negatives’ that is a quantum leap over the
current technologies. Oncosensor should facilitate an early warning,
walk-in, painless, instant cancer diagnosis from outside the body,
without intravenous fluid,” says Dr. Bogdan Maglich, CALSEC’s Chief
Technology Officer and the developer of the core technology that was
originally used for defense, one of “50 Champions of Innovation” elected
by Fast Company magazine. “We derive our confidence from the fact
that our 30 minute measurement of the genome lengths of mammalian
tissues by neutrons yielded the same result as that obtained from a
year-long genome sequencing.”
Oncosensor is not an imager. It will be used in tandem with any one of
the imaging systems which have achieved high sensitivity, almost 98%, in
detecting tumors. But the imagers have a low ‘specificity’, about 70%,
in distinguishing healthy from malignant ones, hence missing an
unacceptably large number of malignancies. California scientists predict
Oncosensor’s specificity may reach 98%, which would be better than the
surgical biopsy.
Dr. Nisar Syed of The Long Beach Cancer Institute, Chancellor of
American College of Radiation Oncology, explained: “Oncosensor has the
potential to significantly enhance the eradication of malignant tumors
by the heat treatment known as hyperthermia, by pointing to the surgeons
the area of least oxygenated tissue.”
“Femto oximetry has also the potential for the forewarning of stroke and
cardiovascular diseases which, too, are marked by oxygen change,” says
co-author Dr. Anna Radovic, a molecular biologist.
CNN and FOX have aired a 5 minute segment on the CALSEC Oncosensor
Collaboration under Leading Developments in Diagnostic Technologies.
It can be viewed at www.calseco.com.